Research Alliance II (Research Alliance II) Total Stockholders Equity : $145.57 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II Total Stockholders Equity?

Research Alliance II's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $145.57 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Research Alliance II's Book Value per Share for the quarter that ended in Sep. 2022 was $7.59. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Research Alliance II's Debt-to-Equity for the quarter that ended in Sep. 2022 was 0.00.

Research Alliance II Total Stockholders Equity Historical Data

The historical data trend for Research Alliance II's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Research Alliance II Total Stockholders Equity Chart

Research Alliance II Annual Data

Trend

Dec20

Dec21

Total Stockholders Equity

0.02

145.36

Research Alliance II Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Stockholders Equity	Get a 7-Day Free Trial			145.51	145.36	145.07	145.08	145.57

Research Alliance II (NAS:RACB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Research Alliance II's Book Value per Share for the quarter that ended in Sep. 2022 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(145.57	-	0)	/	19.1865
	=	7.59

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Research Alliance II's Debt-to-Equity for the quarter that ended in Sep. 2022 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	145.57
	=	0.00

Research Alliance II Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Research Alliance II's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021